P538 Vedolizumab is effective in real life paediatric inflammatory bowel disease: report from the prospective, multi-centre VEDOKIDS cohort study
Z. Shavit-Brunschwig1, O. Ledder1, G. Focht1, D. Urlep2, R. Lev-Tzion1, D. Marcus1, E. Broide3, A. Assa4, S. Hussey5, A. Yerushalmy-Feler6, A. Levine7, J. Markowitz8, C. Norden9, D. Turner*1
1Shaare Zedek Medical Center, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel, 2Children's Hospital University Medical Centre, Department of Gastroenterology, Hepatology and Nutrition, Ljubljana, Slovenia, 3Assaf Harofeh Medical Center, The Kamila Gonczarowski Institute for Gastroenterology and Liver Diseases, Beer Yaakov, Israel, 4Schneider Children's Medical Center, The Institute of Gastroenterology, Nutrition and Liver Diseases, Petah Tikva, Israel, 5Our Lady's Children's Hospital, Crumlin, National Centre for Paediatric Gastroenterology, Dublin, Ireland, 6Tel Aviv Sourasky Medical Center, ‘Dana-Dwek’ Children's Hospital, Pediatric Gastroenterology, Liver and Nutrition Unit, Tel Aviv, Israel, 7Wolfson Medical Center, Pediatric Gastroenterology and Nutrition Unit, Holon, Israel, 8Cohen Children's Medical Center of NY, Division of Pediatric Gastroenterology and Nutrition, New York, USA, 9Hvidovre University Hospital, Department of Paediatrics, Hvidovre, Denmark
Vedolizumab (VDZ) has proven to be effective in adults, both in Crohn’s disease (CD) and ulcerative colitis (UC). Limited data are available in children and none are prospective. We evaluated the short- and mid-term effectiveness and safety of the drug in an interim analysis of the prospective, multi-centre VEDOKIDS cohort study of children with IBD who commenced VDZ.
Although children were managed according to the discretion of the local physician, the study protocol recommended standardised management including VDZ dose of 177 mg/BSA up to 300 mg. Explicit demographic, clinical and safety data were recorded via a REDcap electronic eCRF at weeks 0, 14 and 30. Clinical remission was defined as steroid and EEN-free remission (ie, wPCDAI < 12.5 or PUCAI < 10) without the need for new medications or surgical interventions. Complete remission was defined as clinical remission with CRP
Forty-three children were enrolled, 23 (53%) with CD, and 20 (47%) with UC/IBDU (14 (33%) males, 35 (81%) failed previous anti-TNF, median disease duration 2.3 years (IQR 1.2–5.0)). Four children (9%) discontinued the drug due to primary or secondary non-response and their data were imputed for ITT analysis using the blended non-response imputation and LOCF approach for continuous data. Clinical remission rates at Weeks 14 and 30 were 35% and 30% for CD, and 45% and 45% for UC, respectively. The sustained clinical remission rates (at both Weeks 14 and 30) were 22% in CD and 40% in UC (
In this prospective cohort study, VDZ was safe and effective in a refractory cohort of paediatric IBD. VDZ was numerically more effective in UC/IBD-U than in CD in children, both at Week 14 and Week 30, across all outcomes.
This study is supported by grants from ECCO and ESPGHAN.